异位性皮肤炎市场 - KOL的考察

本报告提供异位性皮肤炎市场相关调查分析，对已上市的治疗方法和开发平台治疗方法的未来性KOL考察。

目录

摘要整理

异位性皮肤炎的未来的治疗范例

调查目的

目前治疗策略

• Dupixent (dupilumab; Sanofi/Regeneron)
  • 重要的考察的彙整
• Adbry/Adtralza (tralokinumab; LEO Pharma)
  • 重要的考察的彙整
• Olumiant (baricitinib; Lilly/Incyte)
  • 重要的考察的彙整
• Cibinqo (abrocitinib; Pfizer)
  • 重要的考察的彙整
• Rinvoq (upadacitinib; AbbVie)
  • 重要的考察的彙整

后期开发平台计划

• Lebrikizumab (Lilly/Almirall)
  • 重要的考察的彙整
• Nemolizumab (Galderma/Chugai/Maruho)
  • 重要的考察的彙整
• Etrasimod (Pfizer)
  • 重要的考察的彙整
• Ivarmacitinib (SHR 0302; Reistone Biopharma)
  • 重要的考察的彙整
• Rocatinlimab (Kyowa Kirin/Amgen)
  • 重要的考察的彙整

对治疗带来影响的初期阶段的开发与其他的因素

• 专家们对 B 244 作为异位性皮肤炎的潜在治疗方法感到惊讶。 附录

附录

What clinical advantages underpin KOLs' opinion that Eli Lilly/Almirall's anti-IL13 lebrikizumab has the potential to disrupt the treatment paradigm and which current therapies could be impacted? Why are experts excited about Kyowa Kirin/Amgen's novel anti-OX40 rocatinlimab and where do they see it delivering value? KOLs critically assess the prospects of launched and pipeline therapies.

In addition to the full report, licensed users have access to the following KOL Bulletins via the Attachments area.

Table of Contents

Executive summary (9)

Future treatment paradigm for atopic dermatitis

Research objectives (1)

Current treatment strategies (43)

• Dupixent (dupilumab; Sanofi/Regeneron) (10)
  • Key insights summary (10)
• Adbry/Adtralza (tralokinumab; LEO Pharma) (11)
  • Key insights summary (11)
• Olumiant (baricitinib; Lilly/Incyte) (8)
  • Key insights summary (8)
• Cibinqo (abrocitinib; Pfizer) (8)
  • Key insights summary (8)
• Rinvoq (upadacitinib; AbbVie) (6)
  • Key insights summary (6)

Late-stage pipeline programmes (34)

• Lebrikizumab (Lilly/Almirall) (6)
  • Key insights summary (6)
• Nemolizumab (Galderma/Chugai/Maruho) (6)
  • Key insights summary (6)
• Etrasimod (Pfizer) (7)
  • Key insights summary (7)
• Ivarmacitinib (SHR 0302; Reistone Biopharma) (6)
  • Key insights summary (6)
• Rocatinlimab (Kyowa Kirin/Amgen) (9)
  • Key insights summary (9)

Earlier-stage developments and other factors impacting treatment (12)

• Experts are underwhelmed by B 244 as a potential therapy for atopic dermatitis (11)
  • KOLs regard lirentelimab as interesting but question whether mast cells and eosinophils play a central role in atopic dermatitis (3)
  • LP 0145 has potential but some experts believe bispecific inhibition or selecting IL22-expressing population may hold more benefit (1)
  • Microbiome involvement in preventing atopic dermatitis is a formidable goal; KOLs agree very limited progress being made (2)
  • New topical formulations will be welcomed in the US; European KOLs are sceptical that they will reach the European market due to high cost (3)

Appendix (4)

• KOL details (4)
  • US KOLs (1)
  • European KOLs (2)